Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 上海微创心脉医疗科技（集团）股份有限公司于2012年在上海国际医学园区注册成立，2019年首批登陆科创板上市（688016.SH），是国家高新技术企业、全国第一批专精特新“小巨人”企业、国家企业技术中心、跨国公司研发中心、国家级“绿色工厂”、上海市科技小巨人企业、上海市企业技术中心、AAA级信用企业，荣获国家知识产权优势企业、上海市质量管理奖、上海市质量标杆、上海品牌等荣誉。 心脉医疗?专注于主动脉及外周血管介入医疗器械的研发、生产、销售和服务，下设4家子公司，包括蓝脉医疗?（主营外周静脉业务）、鸿脉医疗?（主营外周动脉业务）、拓脉医疗?（主营肿瘤介入业务）和美国子公司。公司拥有已上市产品13款，主要涵盖胸主动脉和腹主动脉覆膜支架、术中支架、药物球囊扩张导管以及外周血管支架、球囊扩张导管等产品，其中5款产品获CE认证。截至2023年12月，心脉医疗?的产品已在国内进入超2100家医院，在海外进入31个国家和地区，拯救了全球逾26万名患者的生命。2021年，公司的主动脉腔内介入产品国内市场占有率达29%，在中国市场排名第一。目前公司国内业务覆盖全国31个省区市，国际业务覆盖欧洲、拉美、东南亚等多个地区。 心脉医疗?始终坚持以科技创新为核心驱动力，秉承“要么第一，要么唯一”的创新理念，力求在快速创新中谋发展。近年来，公司每年研发投入占当年营收的15%以上，研发人员占公司员工总数的近30%，并拥有一批国家级和上海市级高精尖科研人才。截至2023年12月，公司累计获得境内外授权专利300余项，其中160余项为境内外发明专利，曾获得中国国家科技进步二等奖，先后2次获得上海市科技进步一等奖。已上市及在研产品中有8款获批进入国家创新医疗器械审批“绿色通道”，处于行业领先地位。重点产品的临床学术合集文章在国际知名医学刊物上获得刊登发表。 公司运营总部位于上海，拥有研发、生产及办公场地近2.4万平方米，拥有符合国家生产Ⅲ类植入产品标准的万级净化车间7000多平方米。秉承“一个属于患者的品牌”的理念，心脉医疗?始终以“为治疗血液循环疾病提供可及性真善美全医疗方案”为使命，致力于通过科技创新建设一个以人为本的全球领先新兴高科技医疗集团。
Main Business 主动脉及外周血管介入医疗器械领域的研发、生产和销售。
Legal Representative 朱清
Top Executives
董事长：Jonathan Chen
董事：霍庆福,孟莎莎,朱清
独立董事：叶小杰,宋成利,史大晓
Top 5 Shareholder
Shareholder name Nature Holding Date
MicroPort Endovascular CHINA Corp.Limited流通A股39.77%29/10/2024
中国银行股份有限公司－华宝中证医疗交易型开放式指数证券投资基金流通A股1.62%29/10/2024
全国社保基金四一三组合流通A股1.03%29/10/2024
香港中央结算有限公司流通A股0.84%29/10/2024
上海微创心脉医疗科技（集团）股份有限公司回购专用证券账户流通A股0.73%29/10/2024
Company Secretary 邱根永
Solicitors 北京市嘉源律师事务所
Auditors 毕马威华振会计师事务所（特殊普通合伙）
Tel No 021-38139300
Fax No 021-33750026
Website www.endovastec.com
Email irm@endovastec.com
Company Address
Register: 上海市浦东新区康新公路3399弄1号
Office: 上海市浦东新区康新公路3399弄1号
Listing Date 22/07/2019
Shares Capital
Shares Capital: 123,262,117
Total A Share: 123,262,117
Listed A Share: 123,262,117
Non-tradable A Share: 0
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 6.810
DPS(RMB)* ¥ 3.000
NBV Per Share(RMB)* ¥ 46.464
Market Capitalization(RMB) 13.767B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.